Inflammatory Disease News and Research RSS Feed - Inflammatory Disease News and Research

Reduce inflammatory reaction by losing weight, says researcher

Reduce inflammatory reaction by losing weight, says researcher

Researchers have found a possible molecular explanation for why overweight is harmful. This new knowledge may provide new drugs for heart attack, stroke, cancer and chronic intestinal inflammation. [More]
Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis. [More]
Physiological variables best predict adult asthma phenotypes

Physiological variables best predict adult asthma phenotypes

Physiological variables are more consistent predictors of adult asthma phenotypes than inflammatory biomarkers, an international team of researchers suggests. [More]
Scientists identify long-overlooked function of vascular smooth muscle cells in atherosclerosis

Scientists identify long-overlooked function of vascular smooth muscle cells in atherosclerosis

Scientists at the Interfaculty Institute of Biochemistry (IFIB) have collaborated with colleagues from the Department of Pharmacy and the Department of Dermatology of the University of Tübingen to identify a long-overlooked function of vascular smooth muscle cells in atherosclerosis. [More]
Black and Hispanic SLE patients are more likely to be readmitted than white patients

Black and Hispanic SLE patients are more likely to be readmitted than white patients

A new study reveals that one in six patients with systemic lupus erythematosus (SLE) is readmitted to the hospital within 30 days of being discharged. [More]
Dimethyl fumarate offers no added benefits for adults with RRMS

Dimethyl fumarate offers no added benefits for adults with RRMS

Dimethyl fumarate has been approved since January 2014 for adults with relapsing remitting multiple sclerosis. [More]
Five-year $10.7M grant to study control, prevention of sexually-transmitted infections

Five-year $10.7M grant to study control, prevention of sexually-transmitted infections

The University of Maryland Schools of Dentistry (UM SOD) and Medicine (UM SOM) jointly announced today that they have received a five-year $10.7 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to study the causes, prevention and treatment of sexually-transmitted diseases (STDs). [More]
Researchers working to develop new drugs for treating chronic inflammatory diseases

Researchers working to develop new drugs for treating chronic inflammatory diseases

Science and industry are collaborating to develop future pharmaceuticals for treating chronic inflammatory diseases. The medicines will combat immunological processes that have gone wrong. [More]
Information about female condom is necessary to communicate with young people

Information about female condom is necessary to communicate with young people

The female condom is one of just two barrier methods that can protect against sexually transmitted infections and unplanned pregnancies, yet many young adults are not aware of the device, a new study by two UT Arlington researchers has found. [More]
Scientists identify genes that may help predict steroid responsiveness in people with EoE

Scientists identify genes that may help predict steroid responsiveness in people with EoE

Results from a clinical trial show that high doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils. [More]
Researchers develop world's first T-cell peptide-based vaccine for heart disease

Researchers develop world's first T-cell peptide-based vaccine for heart disease

Researchers at Wayne State University have made a fundamental discovery and, in subsequent collaboration with scientists at La Jolla Institute for Allergy and Immunology (LIAI), are one step closer to the goal of developing the world's first T-cell peptide-based vaccine for heart disease - the number one killer in the nation. [More]
NIH-funded study identifies genetic markers associated with eosinophilic esophagitis

NIH-funded study identifies genetic markers associated with eosinophilic esophagitis

Scientists funded by the National Institutes of Health have identified genetic markers associated with eosinophilic esophagitis (EoE), an inflammatory disease characterized by high levels of immune cells called eosinophils in the esophagus. [More]
Acute glaucoma is largely an inflammatory disease, say researchers

Acute glaucoma is largely an inflammatory disease, say researchers

Researchers at the University of California, San Diego School of Medicine and Sun Yat-sen University in China have shown that acute glaucoma in mice is largely an inflammatory disease and that high pressure in the eye causes vision loss by setting in motion an inflammatory response similar to that evoked by bacterial infections. [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Research on inflammasomes lays foundations for developing new RA treatments

Research on inflammasomes lays foundations for developing new RA treatments

Patients with more or less severe forms of rheumatoid arthritis (RA) may have the same painful symptoms, but does this mean that the cause of their illness is the same? And therefore that they should all receive the same treatment? Scientists at VIB and Ghent University have demonstrated with their research into inflammasomes that RA should be considered as a syndrome rather than a single disease. [More]
Modified classification system finds over one-third of knee replacements as inappropriate

Modified classification system finds over one-third of knee replacements as inappropriate

New research reports that more than one third of total knee replacements in the U.S. were classified as "inappropriate" using a patient classification system developed and validated in Spain. The study, published in Arthritis & Rheumatology, a journal of the American College of Rheumatology (ACR), highlights the need for consensus on patient selection criteria among U.S. medical professionals treating those with the potential need of knee replacement surgery. [More]
Non-surgical gum disease treatment reduces thickness of wall of arteries

Non-surgical gum disease treatment reduces thickness of wall of arteries

A simple non-surgical gum disease treatment markedly reduces the thickness of the wall of the arteries, a risk factor for heart disease, according to a first of its kind study among Aboriginal Australians. [More]
3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis. [More]
Study shows significantly increased risk of heart attack in patients with Sj-gren's syndrome

Study shows significantly increased risk of heart attack in patients with Sj-gren's syndrome

A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed a significantly increased risk of heart attack in patients with Sj-gren's syndrome (SjS), particularly in the first year following diagnosis. [More]